Publikationen

Moinzadeh P, Riemekasten G, Siegert E, Fierlbeck G, Henes J, Blank N, Melchers I, Mueller-Ladner U, Frerix M, Kreuter A, Tigges C, Lahner N, Susok L, Guenther C, Zeidler G, Pfeiffer C, Worm M, Karrer S, Aberer E, Bretterklieber A, Genth E, Simon JC, Distler JH, Hein R, Schneider M, Seitz CS, Herink C, Steinbrink K, Sárdy M, Varga R, Mensing H, Mensing C, Lehmann P, Neeck G, Fiehn C, Weber M, Goebeler M, Burkhardt H, Buslau M, Ahmadi-Simab K, Himsel A, Juche A, Koetter I, Kuhn A, Sticherling M, Hellmich M, Kuhr K, Krieg T, Ehrchen J, Sunderkoetter C, Hunzelmann N; German Network for Systemic Scleroderma. Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. J Rheumatol. 2016 Jan;43(1):66-74

Avouac J, Walker UA, Hachulla E, Riemekasten G, Cuomo G, Carreira PE, Caramaschi P, Ananieva LP, Matucci-Cerinic M, Czirjak L, Denton C, Ladner UM, Allanore Y; EUSTAR collaborators*; EUSTAR collaborators. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016 Jan;75(1):103-9.

Elhai M, Avouac J, Walker UA, Matucci-Cerinic M, Riemekasten G, Airò P, Hachulla E, Valentini G, Carreira PE, Cozzi F, Balbir Gurman A, Braun-Moscovici Y, Damjanov N, Ananieva LP, Scorza R, Jimenez S, Busquets J, Li M, Müller-Ladner U, Kahan A, Distler O, Allanore Y; EUSTAR co-authors. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016 Jan;75(1):163-9.

Schirmer JH, Bremer JP, Moosig F, Holle JU, Lamprecht P, Wieczorek S, Haenisch S, Cascorbi I. Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. Pharmacogenomics. 2016 Mar;17(4):367-74. doi: 10.2217/pgs.15.176. Epub 2016 Feb 19.

Kerstein A, Müller A, Kabelitz D, Lamprecht P. Effector memory T‑cells in the pathogenesis of ANCA-associated vasculitides. Z Rheumatol. 2016 Feb 25. [Epub ahead of print]

Rademacher J, Kill A, Mattat K, Dragun D, Siegert E, Günther J, Riemekasten G. Monocytic Angiotensin and Endothelin Receptor Imbalance Modulate Secretion of the Profibrotic Chemokine Ligand 18. J Rheumatol. 2016 Mar;43(3):587-91

Mihai C, Landewé R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM, Ionescu R, Rednic S, Allanore Y, Avouac J, Czirják L, Hachulla E, Riemekasten G, Cozzi F, Airò P, Cutolo M, Mueller-Ladner U, Matucci-Cerinic M; EUSTAR co-authors. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis. 2016 Apr;75(4):681-6.

Hegner B, Schaub T, Catar R, Kusch A, Wagner P, Essin K, Lange C, Riemekasten G, Dragun D. Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis. PLoS One. 2016 Apr 7;11(4):e0153101

Smith V, Beeckman S, Herrick AL, Decuman S, Deschepper E, De Keyser F, Distler O, Foeldvari I, Ingegnoli F, Müller-Ladner U, Riccieri V, Riemekasten G, Sulli A, Voskuyl A, Cutolo M; EULAR study group on microcirculation. An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology (Oxford). 2016 May;55(5):883-90.

Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, Papadakis K, Pope J, Matucci-Cerinic M, Furst DE; DUAL-1 Investigators; DUAL-2 Investigators. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. JAMA. 2016 May 10;315(18):1975-88.

Humrich JY1, Riemekasten G2. [IL-2-Therapy in SLE- Selective reconstitution of immunological tolerance].Z Rheumatol. 2016 Jun;75(5):490-2. doi: 10.1007/s00393-016-0129-8.

Hunzelmann N, Riemekasten G, Becker MO, Moinzadeh P, Kreuter A, Melchers I, Mueller-Ladner U, Meier F, Worm M, Lee H, Herrgott I, Pfeiffer C, Fierlbeck G, Henes J, Juche A, Zeidler G, Mensing H, Günther C, Sárdy M, Burkhardt H, Koehm M, Kuhr K, Krieg T, Sunderkötter C. The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies. Br J Dermatol. 2016 Jun;174(6):1384-7.

Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016 Jun 25;387(10038):2630-2640

von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, Enghard P, Sawitzki B, Hiepe F, Radbruch A, Burmester GR, Riemekasten G*, Humrich JY*. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016 Jul;75(7):1407 IF 10.4-15.]

Pischon N, Hoedke D, Kurth S, Lee P, Dommisch H, Steinbrecher A, Pischon T, Burmester GR, Buttgereit F, Detert J, Riemekasten G. Increased Periodontal Attachment Loss in Patients With Systemic Sclerosis. J Periodontol. 2016 Jul;87(7):763-71.

Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He J, Riemekasten G, Vizza CD, Boeckenhoff A, Meier C, de Oliveira Pena J, Denton CP. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2017 Feb;76(2):422-426. doi: 10.1136/annrheumdis-2015-209087. Epub 2016 Jul 25

Wirz EG, Jaeger VK, Allanore Y, Riemekasten G, Hachulla E, Distler O, Airò P, Carreira PE, Tikly M, Vettori S, Balbir Gurman A, Damjanov N, Müller-Ladner U, Distler J, Li M, Häusermann P, Walker UA; EUSTAR coauthors. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis. 2016 Jul;75(7):1285-92

López-Isac E, Campillo-Davo D, Bossini-Castillo L, Guerra SG, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, García de la Peña P; Spanish Scleroderma Group, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, de Vries-Bouwstra J, Herrick A, Worthington J, Denton CP, Fonseca C, Radstake TR, Mayes MD, Martín J. Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. Ann Rheum Dis. 2016 Aug;75(8):1521-6.

Valentini G1, Iudici M1, Walker UA2, Jaeger VK2, Baron M3, Carreira P4, Czirják L5, Denton CP6, Distler O7, Hachulla E8, Herrick AL9, Kowal-Bielecka O10, Pope J11, Müller-Ladner U12, Riemekasten G13, Avouac J14, Frerix M12, Jordan S7, Minier T5, Siegert E14, Ong VH6, Vettori S1, Allanore Y15. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017 Jan;76(1):270-276. doi: 10.1136/annrheumdis-2016-209768. Epub 2016 Sep 12.

Ahrens HC1, Siegert E2, Tomsitz D3, Mattat K2, March C2, Worm M4, Riemekasten G5. Digital ulcers score: a scoring system to assess digital ulcers in patients suffering from systemic sclerosis. Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):142-147. Epub 2016 Oct 13

Humrich JY, Riemekasten G. Clinical trials: The rise of IL-2 therapy - a novel biologic treatment for SLE. Nat Rev Rheumatol. 2016 Dec;12(12):695-696. doi: 10.1038/nrrheum.2016.173. Epub 2016 Oct 20

Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E, Distler O, Airò P, Carreira PE, Balbir Gurman A, Tikly M, Vettori S, Damjanov N, Müller-Ladner U, Distler JH, Li M, Walker UA; EUSTAR co-authors. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS One. 2016 Oct 5;11(10):e0163894

Dobrota R, Maurer B, Graf N, Jordan S, Mihai C, Kowal-Bielecka O, Allanore Y, Distler O; EUSTAR coauthors. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Ann Rheum Dis. 2016 Oct;75(10):1743-8.

Cutolo M, Herrick AL, Distler O, Becker MO, Beltran E, Carpentier P, Ferri C, Inanç M, Vlachoyiannopoulos P, Chadha-Boreham H, Cottreel E, Pfister T, Rosenberg D, Torres JV, Smith V; CAP Study Investigators. Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. Arthritis Rheumatol. 2016 Oct;68(10):2527-39.

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F2, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9.

Klocke J, Kopetschke K, Grießbach AS, Langhans V, Humrich JY, Biesen R, Dragun D, Radbruch A, Burmester GR, Riemekasten G, Enghard P. Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4+ and CD8+ T cells and macrophages. Eur J Immunol. 2017 Jan;47(1):180-192. doi:
10.1002/eji.201646387. Epub 2016 Nov 21.

Wunderlich T, Frey N, Kähler W, Lutz M, Radermacher P, Klapa S, Koch I, Tillmans F, Witte J, Koch A. Influence of hyperoxia on diastolic myocardial and arterial endothelial function. Undersea Hyperb Med. 2017 Nov-Dec;44(6):521-533.

Michelfelder M, Becker M, Riedlinger A, Siegert E, Drömann D, Yu X, Petersen F, Riemekasten G. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. Clin Rheumatol. 2017 Feb;36(2):381-390. doi: 10.1007/s10067-016-3504-6. Epub 2016 Dec 27.

Kerstein A, Schüler S, Cabral-Marques O, Fazio J, Häsler R, Müller A, Pitann S, Moosig F, Klapa S, Haas C, Kabelitz D, Riemekasten G, Wolters S, Lamprecht P. Environmental factor and inflammation-driven alteration of the total peripheral T-cell compartment in granulomatosis with polyangiitis.J Autoimmun. 2017 Mar;78:79-91. doi: 10.1016/j.jaut.2016.12.004. Epub 2016 Dec 28.

Hachulla E, Clerson P, Airò P, Cuomo G, Allanore Y, Caramaschi P, Rosato E, Carreira PE, Riccieri V, Sarraco M, Denton CP, Riemekasten G, Pozzi MR, Zeni S, Mihai CM, Ullman S, Distler O, Rednic S, Smith V, Walker UA, Matucci-Cerinic M, Müller-Ladner U, Launay D; EUSTAR co-workers. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology (Oxford). 2015 Jul;54(7):1262-9. doi: 10.1093/rheumatology/keu450. Epub 2015 Jan 17.

Humrich JY, von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, Burmester GR, Riemekasten G.Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015 Apr;74(4):791-2. doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21.

Humrich JY, Kamradt T, Riemekasten G. [Regulatory T cells and rheumatic diseases].[Article in German]. Z Rheumatol. 2015 Feb;74(1):26-32. doi: 10.1007/s00393-014-1446-4.

Aringer M, Müller-Ladner U, Burkhardt H, Distler JH, Distler O, Graninger WB, Günther C, Hunzelmann N, Kiener H, Sticherling M, Sunderkötter C, Walker UA, Riemekasten G.[Common German language nomenclature for systemic sclerosis]. [Article in German] Z Rheumatol. 2015 Mar;74(2):100-3. doi: 10.1007/s00393-014-1550-5.

Becker MO, Riemekasten G. Reply: vascular receptor autoantibodies in pulmonary arterial hypertension.Am J Respir Crit Care Med. 2015 Mar 1;191(5):602-3. doi: 10.1164/rccm.201412-2322LE.

Kopetschke K, Klocke J, Grießbach AS, Humrich JY, Biesen R, Dragun D, Burmester GR, Enghard P, Riemekasten G. The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. Arthritis Res Ther. 2015 Apr 3;17:94. doi: 10.1186/s13075-015-0600-y.

Schüler S, Wolters S, Pitann S, Kabelitz D, Lamprecht P. Increased co-expression of the natural killer cell receptor NKG2D and further natural killer cell receptors on CD4⁺ T cells in granulomatosis with polyangiitis. Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-183-4. Epub 2015 May 26

Park SH, Chen WC, Durmus N, Bleck B, Reibman J, Riemekasten G, Grunig G.The Effects of Antigen-Specific IgG1 Antibody for the Pulmonary-Hypertension-Phenotype and B Cells for Inflammation in Mice Exposed to Antigen and Fine Particles from Air Pollution. PLoS One. 2015 Jun 16;10(6):e0129910. doi: 10.1371/journal.pone.0129910. eCollection 2015.

Schüler S, Wolters S, Pitann S, Kabelitz D, Lamprecht P. Increased co-expression of the natural killer cell receptor NKG2D and further natural killer cell receptors on CD4⁺ T cells in granulomatosis with polyangiitis. Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-183-4. Epub 2015 May 26.

Avouac J, Riemekasten G, Meune C, Ruiz B, Kahan A, Allanore Y. J Rheumatol. 2015 Oct;42(10):1801-7. doi: 10.3899/jrheum.150061. Epub 2015 Aug 1. Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis.

Millet A, Martin KR, Bonnefoy F, Saas P, Mocek J, Alkan M, Terrier B, Kerstein A, Tamassia N, Satyanarayanan SK, Ariel A, Ribeil JA, Guillevin L, Cassatella MA, Mueller A, Thieblemont N, Lamprecht P, Mouthon L, Perruche S, Witko-Sarsat V. Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis. J Clin Invest. 2015 Nov 2;125(11):4107-21. doi: 10.1172/JCI78182. Epub 2015 Oct 5.

Humrich JX, von Spee C, Riemekasten G. Stärkung der regulatorischen T-Zellen durch Interleukin-2 Therapie. Drug Res (Stuttg). 2015 Nov;65 Suppl 1:S23. doi: 10.1055/s-0035-1558075. Epub 2015 Nov 4. German. No abstract available.

Hellmich B, Lamprecht P, Moosig F. [Vasculitides].[Article in German]Z Rheumatol. 2015 Dec;74(10):852-3. doi: 10.1007/s00393-015-0013-y.

Hunzelmann N, Riemekasten G, Becker M, Moinzadeh P, Kreuter A, Melchers I, Mueller-Ladner U, Meier F, Worm M, Lee H, Herrgott I, Pfeiffer C, Fierlbeck G, Henes J, Juche A, Zeidler G, Mensing H, Günther C,
Sárdy M, Burkhardt H, Koehm M, Kuhr K, Krieg T, Sunderkötter C. The Predict Study: Low risk for digital ulcer development in Systemic Sclerosis patients with increasing disease duration and lack of topoisomerase-1 antibodies. Br J Dermatol. 2015 Dec 26. [Epub ahead of print]

Mueller A, Brieske C, Schinke S, Csernok E, Gross WL, Hasselbacher K, Voswinkel J, Holl-Ulrich K. Plasma cells within granulomatous inflammation display signs pointing to autoreactivity and destruction in granulomatosis with polyangiitis. Arthritis Res Ther. 2014 Feb 20;16(1):R55. doi: 10.1186/ar4490.

Herlyn K, Buckert F, Gross WL, Reinhold-Keller E. Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology (Oxford). 2014 May;53(5):882-9. doi: 10.1093/rheumatology/ket440. Epub 2014 Jan 13.

Mueller A, Brieske C, Schinke S, Csernok E, Gross WL, Hasselbacher K, Voswinkel J, Holl-Ulrich K. Plasma cells within granulomatous inflammation display signs pointing to autoreactivity and destruction in granulomatosis with polyangiitis. Arthritis Res Ther. 2014 Feb 20;16(1):R55. doi: 10.1186/ar4490.

Gross WL, Schreiber S. [Genetic architecture of chronic inflammatory diseases]. Internist (Berl). 2014 Feb;55(2):121-3. doi: 10.1007/s00108-013-3302-z.

Holle JU, Gross WL. [Genetic risk factors for vasculitis].[Article in German] Internist (Berl). 2014 Feb;55(2):128-34. doi: 10.1007/s00108-013-3305-9.

Wieczorek S, Holle JU, Cohen Tervaert JW, Harper L, Moosig F, Gross WL, Epplen JT.The SEM6A6 locus is not associated with granulomatosis with polyangiitis or other forms of antineutrophil cytoplasmic antibody-associated vasculitides in Europeans: comment on the article by Xie et al. Arthritis Rheumatol. 2014 May;66(5):1400-1. doi: 10.1002/art.38367.

Márquez A, Hernández-Rodríguez J, Cid MC, Solans R, Castañeda S, Fernández-Contreras ME, Ramentol M, Morado IC, Narváez J, Gómez-Vaquero C, Martínez-Taboada VM, Ortego-Centeno N, Sopeña B, Monfort J, García-Villanueva MJ, Caminal-Montero L, de Miguel E, Blanco R; Spanish GCA Consortium, Palm O, Molberg O, Latus J, Braun N, Moosig F, Witte T, Beretta L, Santaniello A, Pazzola G, Boiardi L, Salvarani C, González-Gay MA, Martín J. Influence of the IL17A locus in giant cell arteritis susceptibility. Ann Rheum Dis. 2014 Sep;73(9):1742-5. doi: 10.1136/annrheumdis-2014-205261. Epub 2014 Jun 11.

Prüßmann J, Prüßmann W, Recke A, Rentzsch K, Juhl D, Henschler R, Müller S, Lamprecht P, Schmidt E, Csernok E, Görg S, Stöcker W, Zillikens D, Ibrahim SM, Ludwig RJ. Co-occurrence of autoantibodies in healthy blood donors. Exp Dermatol. 2014 Jul;23(7):519-21. doi: 10.1111/exd.12445.

Márquez A, Solans R, Hernández-Rodríguez J, Cid MC3, Castañeda S, Ramentol M, Rodriguez-Rodriguez L, Narváez J, Blanco R, Ortego-Centeno N; Spanish GCA Consortium, Palm O, Diamantopoulos AP, Braun N, Moosig F, Witte T, Beretta L, Lunardi C, Cimmino MA, Vaglio A, Salvarani C, González-Gay MA, Martín J. A candidate gene approach identifies an IL33 genetic variant as a novel genetic risk factor for GCA. PLoS One. 2014 Nov 19;9(11):e113476. doi: 10.1371/journal.pone.0113476. eCollection 2014.

Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry MJ, Amudala N, Smith R, Sivasothy P, Guillevin L, Merkel PA, Jayne DR. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2014 Dec 2. pii: annrheumdis-2014-206095. doi: 10.1136/annrheumdis-2014-206095. [Epub ahead of print]